ACADIA Pharmaceuticals Inc. (ACAD) Financials

$17.46

south_east
-$0.95 (-5.16%)
Day's range
$17.44
Day's range
$18.66

ACAD Income statement / Annual

Last year (2024), ACADIA Pharmaceuticals Inc.'s total revenue was $957.80 M, an increase of 31.85% from the previous year. In 2024, ACADIA Pharmaceuticals Inc.'s net income was $226.45 M. See ACADIA Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $957.80 M $726.44 M $517.24 M $484.15 M $441.76 M $339.08 M $223.81 M $124.90 M $17.33 M $61,000.00
Cost of Revenue $81.84 M $45.73 M $10.17 M $19.14 M $20.55 M $19.60 M $18.33 M $13.06 M $4.41 M $76.37 M
Gross Profit $875.96 M $680.71 M $507.07 M $465.00 M $421.21 M $319.48 M $205.48 M $111.84 M $12.93 M -$76.31 M
Gross Profit Ratio 0.91 0.94 0.98 0.96 0.95 0.94 0.92 0.9 0.75 -1250.95
Research and Development Expenses $303.25 M $351.62 M $361.58 M $239.42 M $319.13 M $240.39 M $187.16 M $149.19 M $99.28 M $73.87 M
General & Administrative Expenses $0.00 $393.07 M $363.59 M $396.03 M $388.66 M $325.64 M $265.76 M $255.06 M $186.46 M $90.80 M
Selling & Marketing Expenses $0.00 $9.40 M $5.50 M $41.80 M $51.10 M $38.30 M $39.80 M $15.60 M $1.60 M $0.00
Selling, General & Administrative Expenses $488.43 M $402.47 M $369.09 M $396.03 M $388.66 M $325.64 M $265.76 M $255.06 M $186.46 M $90.80 M
Other Expenses -$146.52 M $0.00 $3.54 M $2.33 M -$997,000.00 $997,000.00 -$1.84 M $3.98 M $1.33 M $2.50 M
Operating Expenses $645.16 M $754.09 M $730.67 M $635.44 M $707.79 M $566.02 M $452.92 M $404.25 M $285.74 M $164.67 M
Cost And Expenses $727.00 M $799.82 M $740.83 M $654.58 M $728.34 M $585.62 M $471.25 M $417.31 M $290.15 M $164.67 M
Interest Income $25.46 M $17.23 M $6.61 M $591,000.00 $6.61 M $11.17 M $5.35 M $4.13 M $2.76 M $499,000.00
Interest Expense $0.00 $0.00 $6.61 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $15.88 M $5.55 M $2.03 M $3.34 M $2.93 M $2.77 M $3.01 M $2.71 M $1.83 M $647,000.00
EBITDA $100.16 M -$67.83 M -$221.57 M -$167.10 M -$286.59 M -$243.78 M -$244.44 M -$289.70 M -$270.99 M -$163.47 M
EBITDA Ratio 0.1 -0.09 -0.43 -0.35 -0.65 -0.73 -1.11 -2.34 -15.74 -2698.56
Operating Income Ratio 0.24 -0.1 -0.43 -0.35 -0.65 -0.73 -1.11 -2.34 -15.74 -2698.56
Total Other Income/Expenses Net $27.28 M $22.34 M $10.15 M $2.92 M $5.61 M $12.16 M $3.51 M $4.13 M $2.76 M $499,000.00
Income Before Tax $258.08 M -$51.04 M -$213.44 M -$167.52 M -$280.97 M -$234.38 M -$243.94 M -$288.28 M -$270.05 M -$164.11 M
Income Before Tax Ratio 0.27 -0.07 -0.41 -0.35 -0.64 -0.69 -1.09 -2.31 -15.58 -2690.38
Income Tax Expense $31.62 M $10.25 M $2.53 M $351,000.00 $611,000.00 $876,000.00 $1.26 M $1.12 M $1.34 M $330,000.00
Net Income $226.45 M -$61.29 M -$215.98 M -$167.87 M -$281.58 M -$235.26 M -$245.19 M -$289.40 M -$271.39 M -$164.44 M
Net Income Ratio 0.24 -0.08 -0.42 -0.35 -0.64 -0.69 -1.1 -2.32 -15.66 -2695.79
EPS 1.37 -0.37 -1.34 -1.05 -1.79 -1.6 -1.94 -2.36 -2.34 -1.63
EPS Diluted 1.36 -0.37 -1.34 -1.05 -1.79 -1.6 -1.94 -2.36 -2.34 -1.63
Weighted Average Shares Out $165.72 M $163.82 M $161.68 M $160.49 M $157.33 M $147.20 M $126.58 M $122.60 M $115.86 M $100.63 M
Weighted Average Shares Out Diluted $166.36 M $163.82 M $161.68 M $160.49 M $157.33 M $147.20 M $126.58 M $122.60 M $115.86 M $100.63 M
Link